logo

Pluristem Therapeutics, Inc. (PSTI)



Trade PSTI now with
  Date
  Headline
1/9/2018 7:09:18 AM FDA Clears Pluristem' EAP For Use Of PLX-PAD Cell Treatment In Patients With Critical Limb Ischemia
12/12/2017 5:30:38 AM Pluristem Receives A GMP Certification And Manufacturer/importer Authorization From Israel’s Ministry Of Health
12/7/2017 5:17:53 AM Pluristem To Present Data From Its Phase II-equivalent Study Of PLX-R18 Cells For Treatment Of Acute Radiation Syndrome
11/6/2017 7:23:17 AM Pluristem Agrees With Tel Aviv Sourasky Medical Center To Conduct Phase I/II Trial In Steroid-Refractory Chronic GvHD
10/19/2017 7:37:52 AM Pluristem: FDA Grants Orphan Drug Designation For PLX-R18 Cell Therapy For Acute Radiation Syndrome
10/16/2017 7:08:46 AM Pluristem Therapeutics Says New Data Highlights Potential Of PLX Cells In Improving Cardiac Function In Diabetes
10/2/2017 7:12:11 AM Pluristem Therapeutics Says $7.9 Mln Granted To NTRACK Collaborative Project Designed To Study PLX-PAD Cells
9/18/2017 7:04:03 AM FDA Grants Fast Track Designation To Pluristem's PLX-PAD For Treatment Of Critical Limb Ischemia
8/16/2017 7:32:46 AM U.S. DoD To Conduct Studies Of Pluristem’s PLX-R18 In New ARS Project For Use Before Radiation Exposure
7/10/2017 7:08:15 AM AGES Clears Pluristem To Begin Enrollment In Austria For Its Pivotal Phase III Trial Of PLX-PAD Cells
5/3/2017 7:17:15 AM Pluristem Reports Promising Results From Non-Human Primate Pilot Study Of PLX-R18 In Acute Radiation Syndrome
4/19/2017 8:06:20 AM Pluristem Reaches Milestone Of 100 Granted Patents, Incl Coverage Of Over 30 Different Innovations Across Major Markets
2/13/2017 7:08:00 AM Pluristem Therapeutics Says Continuously Working Towards Its Goals For 2017
1/12/2017 6:03:58 AM Pluristem Completes Patient Enrollment In Large Multinational Phase II Trial In Intermittent Claudication
1/10/2017 7:09:12 AM Pluristem’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA
12/27/2016 3:10:09 AM Pluristem And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy